Examkin

Question

Difficulty: HardPediatric Respiratory Disorders

A 9-year-old boy is brought to the emergency department by his parents due to rapidly worsening shortness of breath, a severe cough, and chest tightness over the past 24 hours. He has a history of moderate persistent asthma, and his home regimen includes daily inhaled fluticasone and as-needed albuterol. Over the last 12 hours, he has been using his albuterol inhaler every 2 hours without significant relief. His temperature is 37.1°C (98.8°F), heart rate is 148/min, respiratory rate is 42/min, and blood pressure is 115/72 mmHg. Oxygen saturation is 88% on room air. On physical examination, the patient is speaking only in single words, sitting leaning forward in a tripod position, and exhibiting marked intercostal and suprasternal retractions. Lung auscultation reveals globally poor air entry with very faint expiratory wheezing. Which of the following interventions are indicated in the initial emergency management bundle for this patient? (Select 3)

  1. Continuous nebulized albuterolAnswer
  2. Intravenous methylprednisoloneAnswer
  3. Intravenous magnesium sulfateAnswer
  4. D
    Empiric oral azithromycin
  5. E
    Nebulized hypertonic saline

Answer

The correct interventions are continuous nebulized albuterol, intravenous methylprednisolone, and intravenous magnesium sulfate.
This patient is presenting with severe status asthmaticus, characterized by hypoxia, an inability to speak in full sentences, tripod positioning, and 'silent chest' (poor air entry with faint wheezing due to severe airflow obstruction). The initial management bundle for a life-threatening asthma exacerbation requires immediate aggressive intervention. This includes supplemental oxygen, continuous nebulized short-acting beta-agonists (albuterol), early administration of systemic corticosteroids (intravenous methylprednisolone is preferred over oral preparations to prevent aspiration in a highly dyspneic child), and inhaled anticholinergics (ipratropium). Additionally, intravenous magnesium sulfate is strongly indicated as an adjunctive therapy; it acts as a calcium antagonist to promote smooth muscle relaxation and bronchodilation in severe exacerbations that present with extreme distress or fail to respond to initial therapies.

Step-by-Step Solution

1
Evaluate the patient's clinical presentation and vital signs to determine the severity of the asthma exacerbation.
The patient has hypoxia (SpO2 88%), extreme tachypnea, tripod positioning, an inability to speak in full sentences, and 'silent chest' (poor air entry), confirming a severe and life-threatening asthma exacerbation (status asthmaticus).
Accurate severity stratification is crucial to guide the intensity, route, and choice of pharmacologic therapy.
2
Select the appropriate bronchodilator therapy for severe status asthmaticus.
Continuous nebulized albuterol is chosen.
Continuous administration of short-acting beta-2 agonists provides more sustained bronchodilation than intermittent dosing for patients in severe distress.
3
Determine the optimal route and agent for corticosteroid administration.
Intravenous methylprednisolone is selected.
Systemic corticosteroids are mandatory to reduce airway inflammation. The intravenous route is necessary in patients with severe respiratory distress to minimize the risk of aspiration associated with oral medications.
4
Identify indicated adjunctive therapies for severe, life-threatening exacerbations.
Intravenous magnesium sulfate is selected.
Magnesium sulfate promotes bronchial smooth muscle relaxation and is indicated in severe exacerbations with poor air entry or those refractory to initial beta-agonist therapy.

Key Concept

Management of severe acute asthma exacerbation (status asthmaticus) in pediatric patients
Rate this question

Topics

Pediatric Respiratory Disorders

More questions from this topic